Hemostemix Announces the Incorporation of PreCerv Inc.

June 14, 2022, Calgary, Alberta — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) is pleased to announce it has incorporated PreCerv Inc. (“PreCerv”), as a wholly owned subsidiary. PreCerv will obtain from Hemostemix a global field of use license to NCP-01 and its autologous stem cell technologies, to treat conditions of the central and peripheral nervous system, including but not limited to the following:

  1. Neuropathic pain syndromes.
  2. Traumatic spinal cord injury, chronic brainstem injury, traumatic brain injury, peripheral nerve injury.
  3. Rare diseases including: syringomyelia, Charcot-Marie tooth disease, and Guillain-Barre syndrome, Amyotrophic lateral sclerosis (ALS), age-related macular degeneration (ARMD), corneal or eye diseases and retinopathies of any cause.
  4. Cerebral stroke.